Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed
Start Date
2016
End Date
2019
Financing
Industry
Study Design
To evaluate secukinumab 150 mg s.c. versus placebo in achieving an improvement in
ASDAS at Week 12.
Proportion of patients in each treatment group with improvement in ASDAS at Week 52.
To evaluate secukinumab 300 mg s.c. versus placebo in achieving an improvement in
modified nail psoriasis severity index (mNAPSI) at Week 12 for those patients with nail
psoriasis at Baseline.
To evaluate secukinumab 150 mg s.c. versus placebo in achieving an improvement in
mNAPSI at Week 12 for those patients with nail psoriasis at Baseline.
Proportion of patients in each treatment group with any reduction in mNAPSI score at
Week 52.
To evaluate secukinumab 300 mg s.c. versus placebo in achieving a reduction of bone
marrow edema measured by MRI, i.e. Berlin MRI score for spine and sacroiliac joint at
Week 12.
To evaluate secukinumab 150 mg s.c. versus placebo in achieving a reduction of bone
marrow edema measured by MRI, i.e. Berlin MRI score for spine and sacroiliac joint at
Week 12.
Proportion of patients in each treatment group with any reduction in bone marrow edema
measured by the Berlin MRI score for spine and sacroiliac joint at Week 52
Keywords
Psoriasis Arthritis mit axialer Beteiligung, secukinumab
Homepage
